4D Molecular Therapeutics, Inc. (FDMT) stock

FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value

$12.12−0.88 (-6.74%)

Close on Nov 12, 2026Market cap $874.46MP/E –Yield –

4D Molecular Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

4D Molecular Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in 4D Molecular Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FDMT.

Revenue growth79952.5% · median 72.9%

Operating margin-226.0% · median -299.9%

Net margin-208.6% · median -227.2%

Advertisement
300 × 250

See a number that looks wrong?